London
· Delayed Price · Currency is GBP · Price in USD Alnylam Pharmaceuticals Statistics
Total Valuation
LON:0HD2 has a market cap or net worth of GBP 26.67 billion. The enterprise value is 26.74 billion.
| Market Cap | 26.67B |
| Enterprise Value | 26.74B |
Important Dates
The last earnings date was Thursday, May 1, 2025.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 130.39M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.49% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 125.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 181.55 |
| PS Ratio | 14.67 |
| PB Ratio | 298.48 |
| P/TBV Ratio | 298.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -128.08 |
| EV / Sales | 15.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -458.23 |
Financial Position
The company has a current ratio of 3.04, with a Debt / Equity ratio of 23.58.
| Current Ratio | 3.04 |
| Quick Ratio | 2.84 |
| Debt / Equity | 23.58 |
| Debt / EBITDA | 353.42 |
| Debt / FCF | -36.11 |
| Interest Coverage | -0.79 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1.79% |
| Return on Invested Capital (ROIC) | -2.72% |
| Return on Capital Employed (ROCE) | -3.68% |
| Revenue Per Employee | 814,980 |
| Profits Per Employee | -93,608 |
| Employee Count | 2,230 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +75.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +75.57% |
| 50-Day Moving Average | 252.06 |
| 200-Day Moving Average | 259.65 |
| Relative Strength Index (RSI) | 55.12 |
| Average Volume (20 Days) | 124 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.18 |
Income Statement
In the last 12 months, LON:0HD2 had revenue of GBP 1.82 billion and -208.75 million in losses. Loss per share was -1.62.
| Revenue | 1.82B |
| Gross Profit | 1.56B |
| Operating Income | -89.30M |
| Pretax Income | -275.06M |
| Net Income | -208.75M |
| EBITDA | -44.75M |
| EBIT | -89.30M |
| Loss Per Share | -1.62 |
Balance Sheet
The company has 2.04 billion in cash and 2.11 billion in debt, giving a net cash position of -69.68 million.
| Cash & Cash Equivalents | 2.04B |
| Total Debt | 2.11B |
| Net Cash | -69.68M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 89.35M |
| Book Value Per Share | 0.69 |
| Working Capital | 1.70B |
Cash Flow
In the last 12 months, operating cash flow was -34.92 million and capital expenditures -23.43 million, giving a free cash flow of -58.35 million.
| Operating Cash Flow | -34.92M |
| Capital Expenditures | -23.43M |
| Free Cash Flow | -58.35M |
| FCF Per Share | n/a |
Margins
Gross margin is 86.01%, with operating and profit margins of -4.91% and -11.49%.
| Gross Margin | 86.01% |
| Operating Margin | -4.91% |
| Pretax Margin | -15.13% |
| Profit Margin | -11.49% |
| EBITDA Margin | -2.46% |
| EBIT Margin | -4.91% |
| FCF Margin | n/a |
Dividends & Yields
LON:0HD2 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.49% |
| Shareholder Yield | -2.49% |
| Earnings Yield | -0.78% |
| FCF Yield | -0.22% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0HD2 has an Altman Z-Score of 3.05.
| Altman Z-Score | 3.05 |
| Piotroski F-Score | n/a |